Johnson & Johnson

Pic:getty/mikemareen

Merck to help manufacture J&J COVID-19 vaccine

By Rachel Arthur

Merck’s US facilities will help manufacture Johnson & Johnson’s COVID-19 vaccine: which a $268.8m injection from the US government helping it adapt existing facilities for COVID-19 vaccines and medicines.

Pic:getty/bankrx

FDA says J&J COVID-19 vaccine is effective and safe

By Rachel Arthur

The FDA has outlined its analysis of Johnson & Johnson's single-shot COVID-19 vaccine, ahead of a meeting of the Vaccines and Related Biological Products Advisory Committee Meeting to assess the candidate's application for Emergency Use...

Pic:getty/bankrx

J&J submits EUA application for single-shot COVID-19 vaccine

By Rachel Arthur

J&J pledges to start shipping doses of its COVID-19 vaccine in the US as soon as Emergency Use Authorization (EUA) is received from the Food and Drug Administration, while it plans to apply for Conditional Marketing Authorization in the EU in the...

Pic:getty/dolgachov

Janssen acquires rights to novel AMD gene therapy

By Rachel Arthur

Janssen Pharmaceuticals, Inc. has acquired the rights to Hemera Biosciences’ investigational gene therapy HMR59: which has been designed to help preserve vision in patients with severe age-related macular degeneration (AMD).

J&J has now taken its COVID-19 vaccine into Phase 3 trials for both a 1-dose and 2-dose regimen. Pic:getty/JHDTstockimages

J&J launches Phase 3 trial for 2-dose COVID-19 vaccine

By Rachel Arthur

Johnson & Johnson has launched a second global Phase 3 trial for its Janssen COVID-19 vaccine candidate: this time exploring a 2-dose regimen (its existing Phase 3 trial is for a 1-dose regimen).

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers